Carregant...
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy
BACKGROUND: The optimal timing to initiate bevacizumab (BV) therapy for recurrent glioblastoma (GBM) is currently unclear. To address this issue, we examined progression-free survival (PFS) and survival time (ST) in a large retrospective cohort of GBM patients treated with BV at different recurrence...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4022228/ https://ncbi.nlm.nih.gov/pubmed/24627236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou028 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|